038 A New Four-Drug Treatment for Myeloma: What Does DVRD Mean for Patients?

Experts discuss the approval of the new DVRD four-drug treatment for newly diagnosed myeloma patients who are not eligible for a stem cell transplant, exploring its benefits, risks and how treatment decisions are personalised.📌Key Takeaways: New four-drug treatment now available in England and Wales Deeper remissions and longer disease control for many patients  Why the “best” treatment depends on you, not just the disease  For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/The Myeloma UK InfoLine is: 0800 980 3332This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concernsABOUT YOUR HOSTSDr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity. Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.